社区

$Moderna, Inc.(MRNA)$ Even if we assume their management was good, mass manufacturing will be inherently more difficult for Novavax because they are using living cells to produce their vaccine meaning that a purification step is required and QC of the final product will be challenging. The vaccine itself as a prime is good on par with the mRNA vaccines but it is inferior to mRNA vaccines when used as boosters. Considering that most in the developed world already got their prime, this point is particularly inconvenient for their investors although they may ride on some short term SP catalysts.$Novavax(NVAX)$